Friday, July 10, 2026

pharma · sickle cell anaemia · Chronic Obstructive Pulmonary Disease

Pierre Fabre Medical

Pierre Fabre Australia is a pharma organization headquartered in AU. Primary therapeutic focus areas include sickle cell anaemia, Chronic Obstructive Pulmonary Disease. NovaPharmaNews links 3 clinical program(s), 2 drug

North Sydney, AU HQ
2002 Founded
5 Employees
TGA registrant Type
Company details
Status
Public
HQ
North Sydney, AU
Founded
2002
Employees
5
Programs
3
Drugs
18
Patents
0
Clinical program

The papillon study

Approved · small molecule · giving a commercially available vaccine to women with HIV under treatment, women living with HIV traeted by antiretroviral

The papillon study for giving a commercially available vaccine to women with HIV under treatment, women living with HIV traeted by antiretroviral is a Approved program (small_molecule) at Pierre Fabre Australia Pty Ltd with 1 ClinicalTrials.gov record(s).

Internal code The papillon study

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Pierre Fabre Australia Pty Ltd
Phase
Approved
Modality
small_molecule
Indication
giving a commercially available vaccine to women with HIV under treatment, women living with HIV traeted by antiretroviral
Status
active
Trials
1